Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Lexicon Pharmaceuticals Stories

2012-04-25 14:21:37

THE WOODLANDS, Texas, April 25, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will release its first quarter 2012 financial results on Thursday, May 3, 2012 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss financial results for the quarter and program status at 11:00 a.m. Eastern Time that same day. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or...

2012-03-27 14:20:54

THE WOODLANDS, Texas, March 27, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 11th Annual Needham Healthcare Conference in New York on Tuesday, April 3, 2012 at 10:00 a.m. Eastern Time. Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones. A live webcast of the presentation will be available through Lexicon's...

2012-03-20 14:20:59

THE WOODLANDS, Texas, March 20, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract and is characterized by severe diarrhea and flushing episodes with...

2012-02-29 17:00:00

THE WOODLANDS, Texas, Feb. 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Cowen and Company 32nd Annual Health Care Conference in Boston on Monday, March 5, 2012, at 3:30 p.m. Eastern Time. Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones. A live webcast of the presentation will be available...

2012-02-23 17:00:00

THE WOODLANDS, Texas, Feb. 23, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the RBC Healthcare Conference in New York on Tuesday, February 28, 2012, at 10:30 a.m. Eastern Time. Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones. A live webcast of the presentation will be available through Lexicon's corporate...

2012-02-22 05:00:00

THE WOODLANDS, Texas, Feb. 22, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2011. "We made substantial progress with our drug pipeline in 2011, highlighted by the positive results obtained from clinical studies of LX4211 in diabetes and...

2012-02-16 17:31:00

THE WOODLANDS, Texas, Feb. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, will release its fourth quarter and year end 2011 financial results on Wednesday, February 22, 2012 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2011...

2012-02-07 17:00:00

THE WOODLANDS, Texas, Feb. 7, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 2012 BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012 at 10:00 a.m. Eastern Time. At the conference, which is hosted by the Biotechnology Industry Organization (BIO), Dr. Sands will provide an overview on Lexicon's clinical development programs and...

2012-01-09 15:30:00

THE WOODLANDS, Texas, Jan. 9, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl peptidase 4 (DPP-4) inhibitor, sitagliptin (Januvia®), one of the most widely prescribed diabetes drugs. "The results of this study are important given that combination...

2012-01-05 15:22:00

WINSTON-SALEM, N.C., Jan. 5, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced it has completed the relocation of its corporate headquarters from East Norriton, Pennsylvania to the Company's existing facility in Winston-Salem, North Carolina. The relocation is part of the Company's previously announced restructuring, which was designed to fund the Company's lead development programs through key milestones in 2012 while reducing anticipated...